Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Gene variant in Andean populations could help predict blood cancer treatment outcomes

Two researchers from Huntsman Cancer Institute at the University of Utah (the U) have discovered a gene variant found in high-altitude Andean populations that they believe could be a new biomarker for predicting the severity of diseases and treatment responses for certain types of blood cancer.

14 Dec 2024

Adjuvant anthracycline- plus taxane-based chemotherapy regimen improves survival in high-risk breast cancer patients

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy regimens compared with those receiving adjuvant taxane-based chemotherapy regimens alone, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest results from the phase III OlympiA clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Mayo Clinic researchers advocate for comprehensive TPMT genotyping across ancestries

Mayo Clinic researchers found that a gene variant, the TPMT∗8 allele, is associated with reduced metabolism of the thiopurine class of drugs. TPMT∗8 is relatively common in individuals of African or African American descent. A novel study in The Journal of Molecular Diagnostics, published by Elsevier, details the researchers' goal to provide pharmacogenomic testing that can be used clinically to predict drug response that is beneficial to all patients, regardless of their ancestral background.

11 Dec 2024

New triplet therapies show promise for relapsed and newly diagnosed leukemias

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias.

9 Dec 2024

First-in-class monoclonal antibody shows promise for rare, aggressive hyperinflammatory condition

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.

9 Dec 2024

New advances offer hope for patients with systemic mastocytosis

Dana-Farber Cancer Institute researchers are breaking new ground in the fight against systemic mastocytosis, a rare and heterogeneous condition that is often challenging for clinicians to accurately diagnose and treat.

9 Dec 2024

Novel drug combination shows promise for CLL treatment

A novel, fixed-duration drug combination - consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug - shows deep and durable responses in patients with chronic lymphocytic leukemia (CLL), Dana-Farber Cancer Institute investigator Jennifer Brown, MD, PhD, reports at the 66th American Society for Hematology (ASH) Annual Meeting and Exposition, on behalf of the trial investigators.

9 Dec 2024

Breakthrough treatment improves survival rates for children with B-ALL

Just days before his fourth birthday, Santiago was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL), the most common cancer in children.

9 Dec 2024

Mapping blood system changes offers new hope for leukemia treatments

Researchers at University of California San Diego School of Medicine and their colleagues have developed the first comprehensive map of the dramatic changes that take place in the blood system over the course of the human lifetime.

6 Dec 2024

New collaborative effort aims to cure ALK-positive lung cancer

Lung cancer is the leading cause of cancer death worldwide, with various subtypes affecting millions of people each year.

6 Dec 2024

EZH2 inhibitors enhance effectiveness of cancer immunotherapies

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma researchers.

5 Dec 2024

Innovative approach predicts most effective medication for cancer patients

A new method can improve treatment for patients with chronic myeloid leukemia by predicting which medication will be most effective.

4 Dec 2024

New study explores obecabtagene autoleucel for adults with hard-to-treat leukemia

FELIX study results reveal obe-cel's potential in relapsed B-cell ALL, achieving 77% remission with low severe toxicity, enhancing CAR T-cell therapy outcomes.

2 Dec 2024

Scientists identify drug-resistant bone marrow cells linked to poor outcomes in fast-growing leukemia

Researchers explore treatment resistance and relapse in T-cell acute lymphoblastic leukemia.

29 Nov 2024

Obe-cel demonstrates strong efficacy and safety in treating leukemia

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high response rates and most did not need a subsequent stem cell transplant (SCT), according to results from the Phase Ib/II FELIX trial co-led by researchers at The University of Texas MD Anderson Cancer Center.

27 Nov 2024

Epigenetic profiles of blood cancer cells could aid in diagnosis and treatment

Research in biomedical laboratories has been changing significantly in recent years, to the point that test tubes have given way to computers on many occasions.

27 Nov 2024

Multiomic signatures identified for rapid detection and treatment of high-risk T-ALL

Researchers from Children's Hospital of Philadelphia (CHOP) have discovered the underlying biology that identifies a subset of patients with acute lymphoblastic leukemia who have a higher risk version of the disease and are more likely to relapse despite treatment.

25 Nov 2024

Could medical imaging innovation be the catalyst for precision medicine?

Precision medicine leverages genetic and lifestyle data to customize treatments, enhancing healthcare efficiency and patient outcomes in disease management.

24 Nov 2024

Nanoparticle coating enhances cancer drug delivery and reduces side effects

A spoonful of sugar might actually help the medicine go down, according to recent research from the University of Mississippi. And it could reduce the harmful side effects of cancer treatment.

21 Nov 2024

Leukemia News and Research

Further Reading

Gene variant in Andean populations could help predict blood cancer treatment outcomes

Adjuvant anthracycline- plus taxane-based chemotherapy regimen improves survival in high-risk breast cancer patients

Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients

Mayo Clinic researchers advocate for comprehensive TPMT genotyping across ancestries

New triplet therapies show promise for relapsed and newly diagnosed leukemias

First-in-class monoclonal antibody shows promise for rare, aggressive hyperinflammatory condition

New advances offer hope for patients with systemic mastocytosis

Novel drug combination shows promise for CLL treatment

Breakthrough treatment improves survival rates for children with B-ALL

Mapping blood system changes offers new hope for leukemia treatments

New collaborative effort aims to cure ALK-positive lung cancer

EZH2 inhibitors enhance effectiveness of cancer immunotherapies

Innovative approach predicts most effective medication for cancer patients

New study explores obecabtagene autoleucel for adults with hard-to-treat leukemia

Scientists identify drug-resistant bone marrow cells linked to poor outcomes in fast-growing leukemia

Obe-cel demonstrates strong efficacy and safety in treating leukemia

Epigenetic profiles of blood cancer cells could aid in diagnosis and treatment

Multiomic signatures identified for rapid detection and treatment of high-risk T-ALL

Could medical imaging innovation be the catalyst for precision medicine?

Nanoparticle coating enhances cancer drug delivery and reduces side effects

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News